Novel triplex-engineered, BRCA1-mutated cell lines for research
Novel triplex-engineered, BRCA1-mutated cell lines for research
批准号:
8412753
负责人:
PETER M GLAZER
金额:
$24.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-01-13 至 2013-12-31
关键词:
AddressAlkylating AgentsAllelesBRCA1 MutationBRCA1 ProteinBRCA1 geneBiological AssayBiologyBreastCancer BiologyCell CycleCell LineCell physiologyCellsCharacteristicsCodeCommunitiesDNADNA DamageDNA RepairDevelopmentDouble Strand Break RepairEngineeringEpithelial CellsFoundationsFunding MechanismsGenesGenotypeGrowthHereditary Malignant NeoplasmHumanHuman Cell LineInheritedKaryotypeKnock-outMalignant neoplasm of ovaryMammary glandMediatingMessenger RNAMethodologyModelingModificationMutateMutationNon-MalignantPhasePoint MutationPredispositionResearchResourcesSFN geneSister Chromatid ExchangeTechniquesTechnologyTelomeraseTestingTimeTranscriptional RegulationWomanWorkbasecarcinogenesiscrosslinkdesignmalignant breast neoplasmmutantnovelresponsetriple helix
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Women with one inherited mutation in the BRCA1 gene have a substantially increased predisposition to breast and ovarian cancer. However, focused study of the impact of specific BRCA1 mutations and, importantly, of heterozygosity at the BRCA1 locus, on the biology of breast epithelial cells and on breast carcinogenesis has been hampered by the lack of suitable human cell line models. To address this shortcoming, we propose to engineer novel human breast-derived, non-malignant cell lines using triplex-helix-based gene editing technology to introduce precisely defined genotypes at the BRCA1 locus. These genotypes will consist of wild-type, heterozygous, or homozygous mutations at the BRCA1 gene for two of the common deleterious alleles found in human familial cancers (185delAG and 5382insC). These unique matched sets of BRCA1 wild-type, heterozygous, and homozygous mutant cell lines will enable physiologically relevant comparisons between otherwise isogenic, breast-derived cells with defined genotypes for BRCA1. We will characterize these cells for key aspects of BRCA1 function, including regulation of transcription and of DNA damage responses and DNA repair.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:10198735
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:9804726
-
项目类别:
-
资助金额:$42.11万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:10414795
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
-
批准号:10274829
-
项目类别:
-
资助金额:$75.68万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
-
批准号:10706300
-
项目类别:
-
资助金额:$114.48万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for targeted delivery of gene editing agents to treat cystic fibrosis in animal models: SCGE Disease Models Studies Supplement
-
批准号:10619840
-
项目类别:
-
资助金额:$49.82万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:9388067
-
项目类别:
-
资助金额:$77.33万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:10204894
-
项目类别:
-
资助金额:$100.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:10456727
-
项目类别:
-
资助金额:$98.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:9981673
-
项目类别:
-
资助金额:$100.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10170726
-
项目类别:
-
资助金额:$44.14万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10394345
-
项目类别:
-
资助金额:$40.59万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10599891
-
项目类别:
-
资助金额:$45.59万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Bifunctional Antibodies for Melanoma Therapy
-
批准号:8755327
-
项目类别:
-
资助金额:$45.94万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
In vivo genomic editing of hematopoietic cells for HIV resistance
-
批准号:9110812
-
项目类别:
-
资助金额:$60.79万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Bifunctional Antibodies for Melanoma Therapy
-
批准号:8916650
-
项目类别:
-
资助金额:$44.27万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Center NCTN
-
批准号:8605651
-
项目类别:
-
资助金额:$55.15万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
-
批准号:8500076
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2013
-
负责人:PETER M GLAZER
-
依托单位:
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
-
批准号:8826075
-
项目类别:
-
资助金额:$34.55万
-
财政年份:2013
-
负责人:PETER M GLAZER
-
依托单位:
Novel triplex-engineered, BRCA1-mutated cell lines for research
-
批准号:8239269
-
项目类别:
-
资助金额:$20.71万
-
财政年份:2012
-
负责人:PETER M GLAZER
-
依托单位:
海外基金